Thursday, January 27, 2022
HomeLatest NewsCovid-19Joint CDC and FDA Statement on J&J Covid Vaccine

Joint CDC and FDA Statement on J&J Covid Vaccine

U.S. Department of Health & Human Services (HHS) released a joint statement from the Centers of Disease Control (CDC) and Federal Drug Administration (FDA) on the Johnson & Johnson COVID-19 Vaccine. Based on six reported cases of a rare and severe type of blood clot, HHS recommends that vaccine providers pause on administering the Johnson & Johnson (J&J) COVID-19 vaccine.

The CDC’s Advisory Committee on Immunization Practices (ACIP) is meeting April 14 and will provide updates. The CDC and FDA will provide additional information and answer questions at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.

People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System.

Stay Connected

Unified Voice Newsletter

Events This Month

january

27jan12:00 pm1:00 pmSD Dimensions: Reports and DashboardsSDAHO Webinar12:00 pm - 1:00 pm CST Event Type :Education Events,Webinar

28jan9:00 am12:00 pmSDSU Nursing Career Fair9:00 am - 12:00 pm CST

X


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact